Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | The DNA damaging revolution

Aberrations within cancer cell genomes can be capitalized for therapeutic benefit. Thomas Helleday, PhD, of the University of Sheffield, Sheffield, UK, discusses this and how ovarian cancer patients may ultimately be impacted. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.